endpts.com·Jun 18, 2026
RA Capital, Forbion, and Sanofi Ventures are reportedly investing in a new eye drug developed by a biotech company from Korea, continuing the trend of major venture investors collaborating to support innovative medical treatments.
The notable insight for someone in your field is that major venture investors like RA Capital, Forbion, and Sanofi Ventures are backing a new experimental eye drug from Korea. This highlights a growing trend where prominent venture capital groups collaborate to support innovative biotechnologies, indicating potential investment opportunities and a focus on novel therapeutics in the ophthalmology sector.